Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR)
Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Sponsor: Acute Leukemia French Association
A PHASE2 clinical study on AML, Adult and FLT3-ITD, this trial is actively recruiting participants. The trial is conducted by Acute Leukemia French Association and has accumulated 7 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jan 2024 — Mar 2024 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Acute Leukemia French Association
- French Innovative Leukemia Organisation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Angers, France , Clamart, France , Clermont-Ferrand, France , Créteil, France , Grenoble, France , Lille, France , Limoges, France , Lyon, France , Marseille, France and 10 more locations